DR. CASSANDRA N MOORE M.D. NPI 1114966298

NPI Details

DR. Cassandra N Moore, M.D. is a hematology and oncology internal medicine in Scottsdale, AZ with 27 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Cassandra N Moore, M.D. NPI is 1114966298. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

Education
Medical School: UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE
Graduation Year:1999

The provider's business location address is:

13400 E SHEA BLVD
SCOTTSDALE, AZ
ZIP 85259-452
Phone: (480) 301-8000
Fax: (919) 852-0321

The NPI 1114966298 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, paclitaxel protein-bound particles, 1 mg (HCPCS:J9264)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, docetaxel, 1 mg (HCPCS:J9171)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, lanreotide, 1 mg (HCPCS:J1930)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, decitabine, 1 mg (HCPCS:J0894)
• Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg (HCPCS:Q5116)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, etoposide, 10 mg (HCPCS:J9181)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Collection of blood sample from implanted device (HCPCS:36591)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Telephone medical discussion with physician, 21-30 minutes (HCPCS:99443)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Infusion, normal saline solution, 250 cc (HCPCS:J7050)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Injection of drug or substance into vein (HCPCS:96374)

The enumeration date for this NPI number is 6/5/2006 and was last updated on 9/8/2020.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: